Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03143569 · ClinicalTrials.gov registry record · NA
Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial
A NA study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT03143569 is a NA study that has completed, run by Washington University School of Medicine. The registered enrollment target is 20 participants.
The verdict
NCT03143569, a NA study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study evaluates two different methods for monitoring a patient's anti-clotting \[heparin\] therapy after they receive a heart pump implant \[left ventricular assist device -LVAD\]. One method tests for how long it takes the patient's blood to clot and uses that to determine if they are on the right dose of heparin. The other method uses a more direct measure of how much heparin is in the blood. The hypothesis is that the method that more directly measures how much heparin is in the patient's blood will provide better medical results for the patient's care after they have the heart pump implant. To that end, the investigators are conducting this feasibility trial to establish the logistics associated with the implementation of these heparin monitoring approaches.
Interventions
- DEVICE aPTT guided heparin management
- DEVICE Anti-factor Xa guided heparin management
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-05-20 |
| Est. Completion | 2018-07-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03143569
The ClinicalTrials.gov registry entry for NCT03143569 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which aPTT guided heparin management is the first listed.
NCT03143569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03143569 about?
NCT03143569 is a clinical study titled "Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial". This study evaluates two different methods for monitoring a patient's anti-clotting \[heparin\] therapy after they receive a heart pump implant \[left ventricular assist device -LVAD\]. One method tests for how long it takes the patient's blood to clot and uses that to determine if they are on the r...
What is the current status of trial NCT03143569?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2017-05-20. Estimated completion is 2018-07-12.
What interventions are being tested in trial NCT03143569?
The interventions under investigation include: aPTT guided heparin management (DEVICE), Anti-factor Xa guided heparin management (DEVICE).
Who is sponsoring clinical trial NCT03143569?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.